Condition (MeSH)
Carcinoma, Small Cell
ClinicalTrials.gov lists 55 trials for Carcinoma, Small Cell or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 4.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
55 of the 55 trials are tagged with Carcinoma, Small Cell itself; the rest are tagged with a narrower condition beneath it.
When did Carcinoma, Small Cell trials start? (23)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 3
- Not applicable
- Observational
Top of scale: 6
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 2 |
| 2024 | 1 |
| 2023 | 1 |
| 2022 | 3 |
| 2021 | 4 |
| 2019 | 1 |
| 2018 | 2 |
| 2017 | 4 |
| 2016 | 4 |
Showing 10 of 23 earlier years.
No forecast is made for this condition: it averages 2.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Carcinoma, Small Cell trials in? (6)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 10 |
| Phase 1/2 | 10 |
| Phase 2 | 20 |
| Phase 3 | 4 |
| Not applicable | 4 |
| Observational | 7 |
How many Carcinoma, Small Cell trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 4 |
| Active, not recruiting | 3 |
| Completed | 30 |
| Terminated | 10 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Carcinoma, Small Cell trials? (12)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Cancer Institute (NCI) | 4 |
| Eli Lilly and Company | 2 |
| EpicentRx, Inc. | 2 |
| Valerio Therapeutics | 2 |
| Advaxis, Inc. | 1 |
Showing 5 of 12 sponsors.
Which drugs are being tested for Carcinoma, Small Cell? (4)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| TOPOTECAN | 4 |
| PEMBROLIZUMAB | 3 |
| Belinostat | 2 |
| (nab)-paclitaxel | 2 |
Interventions as named in the registry (11)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Cisplatin 1 | 6 |
| Etoposid | 4 |
| Pemetrexe | 3 |
| or carboplatin | 2 |
| SOC: Temozolomide | 2 |
Showing 5 of 11 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Carcinoma, Small Cell trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Neutrophil count decreased | 44 | 2 |
| Pleural effusion | 28 | 5 |
| Anemia | 24 | 3 |
| Death not associated with CTCAE term - Disease Progression NOS | 17 | 2 |
| Fatigue | 13 | 7 |
Showing 5 of 10 adverse events.
Which publications cover Carcinoma, Small Cell? (270)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| A phase II study of lurbinectedin with or without avelumab in small cell carcinoma of the bladder (laser)-design and rationale. | Future oncology (London, England) | 2025 | Yes |
| Agnostic phase II, multicenter, single-arm study with DURVAlumab plus carboplatin or cisplatin and etoposide as first-line treatment in extensive stage - Extrapulmonary Small Cell Carcinoma (EPSCC) patients - DURVASCC trial (GOIRC-01-2021). | BMC cancer | 2025 | Yes |
| Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tract. | Gynecologic oncology | 2020 | Yes |
| Treatment and outcome of 432 patients with extensive-stage small cell lung cancer in first, second and third line - Results from the prospective German TLK cohort study. | Lung cancer (Amsterdam, Netherlands) | 2019 | Yes |
| The genomic landscape of small cell carcinoma of the esophagus. | Cell research | 2018 | Yes |
Showing 5 of 270 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.